Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) from a hold rating to a sell rating in a report released on Saturday,Wall Street Zen reports.

Several other equities research analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Guggenheim raised their price target on Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a report on Friday, September 25th. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Monday, July 27th. They issued a “buy” rating and a $50.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $46.50.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of NASDAQ:DMRA opened at $21.60 on Friday. The firm has a fifty day moving average price of $23.35 and a two-hundred day moving average price of $25.76. Damora Therapeutics, Inc. Common Stock has a one year low of $4.95 and a one year high of $38.33. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -6.41 and a beta of 1.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.06. Equities research analysts expect that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Activity at Damora Therapeutics, Inc. Common Stock

In related news, CEO Jennifer Jarrett purchased 12,500 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were purchased at an average price of $20.23 per share, with a total value of $252,875.00. Following the acquisition, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. This represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.40% of the stock is owned by insiders.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently made changes to their positions in the stock. Arizona State Retirement System bought a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at $260,000. Squarepoint Ops LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at about $303,000. Seven Fleet Capital Management LP purchased a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter valued at about $7,398,000. Finally, Braidwell LP bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $42,146,000. 14.20% of the stock is owned by institutional investors.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.